Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Among authors: vullo v. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
Virologic correlates of adherence to antiretroviral medications and therapeutic failure.
Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A, Vullo V, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Perno CF, et al. Among authors: vullo v. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S118-22. doi: 10.1097/00126334-200212153-00006. J Acquir Immune Defic Syndr. 2002. PMID: 12562033 Review.
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.
Sarmati L, Nicastri E, Uccella I, D'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Concia E, Vullo V, Vella S, Andreoni M. Sarmati L, et al. Among authors: vullo v. J Clin Microbiol. 2003 Apr;41(4):1760-2. doi: 10.1128/JCM.41.4.1760-1762.2003. J Clin Microbiol. 2003. PMID: 12682180 Free PMC article.
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.
Nicastri E, Sarmati L, d'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Montano M, Uccella I, Amici R, Gatti F, Vullo V, Concia E, Vella S, Andreoni M. Nicastri E, et al. Among authors: vullo v. J Clin Microbiol. 2003 Jul;41(7):3007-12. doi: 10.1128/JCM.41.7.3007-3012.2003. J Clin Microbiol. 2003. PMID: 12843034 Free PMC article. Clinical Trial.
Viral growth assay to evaluate the replicative capacity of HIV-1 isolates.
Nicastri E, Sarmati L, Dori L, Montano M, d'Ettorre G, Buonomini AR, Parisi SG, Concia E, Vullo V, Andreoni M. Nicastri E, et al. Among authors: vullo v. J Virol Methods. 2004 Feb;115(2):199-205. doi: 10.1016/j.jviromet.2003.09.032. J Virol Methods. 2004. PMID: 14667536
551 results